Summary
According to APO Research, the global Drugs for Spinal Muscular Atrophy (SMA) market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Drugs for Spinal Muscular Atrophy (SMA) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Drugs for Spinal Muscular Atrophy (SMA) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Drugs for Spinal Muscular Atrophy (SMA) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Drugs for Spinal Muscular Atrophy (SMA) include Novartis, Ionis Pharmaceuticals, Genentech and Biogen, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Drugs for Spinal Muscular Atrophy (SMA), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Spinal Muscular Atrophy (SMA).
The report will help the Drugs for Spinal Muscular Atrophy (SMA) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Drugs for Spinal Muscular Atrophy (SMA) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Drugs for Spinal Muscular Atrophy (SMA) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Drugs for Spinal Muscular Atrophy (SMA) Segment by Company
Novartis
Ionis Pharmaceuticals
Genentech
Biogen
Drugs for Spinal Muscular Atrophy (SMA) Segment by Type
Oral Drugs
Injections
Drugs for Spinal Muscular Atrophy (SMA) Segment by Application
Hospital
Clinic
Other
Drugs for Spinal Muscular Atrophy (SMA) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Spinal Muscular Atrophy (SMA) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drugs for Spinal Muscular Atrophy (SMA) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Spinal Muscular Atrophy (SMA).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Drugs for Spinal Muscular Atrophy (SMA) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Drugs for Spinal Muscular Atrophy (SMA) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Drugs for Spinal Muscular Atrophy (SMA) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
- Preface
- Scope of Report
- Reasons for Doing This Study
- Research Methodology
- Research Process
- Data Source
- Secondary Sources
- Primary Sources
- Market Overview
- Product Definition
- Global Market Growth Prospects
- Global Drugs for Spinal Muscular Atrophy (SMA) Market Size (2020-2031)
- Global Drugs for Spinal Muscular Atrophy (SMA) Sales (2020-2031)
- Global Drugs for Spinal Muscular Atrophy (SMA) Market Average Price (2020-2031)
- Drugs for Spinal Muscular Atrophy (SMA) by Type
- Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Oral Drugs
- Injections
- Drugs for Spinal Muscular Atrophy (SMA) by Application
- Market Value Comparison by Application (2020 VS 2024 VS 2031)
- Hospital
- Clinic
- Other
- Market Competitive Landscape by Manufacturers
- Global Drugs for Spinal Muscular Atrophy (SMA) Market Competitive Situation by Manufacturers (2020 Versus 2024)
- Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units) of Manufacturers (2020-2025)
- Global Drugs for Spinal Muscular Atrophy (SMA) Revenue of Manufacturers (2020-2025)
- Global Drugs for Spinal Muscular Atrophy (SMA) Average Price by Manufacturers (2020-2025)
- Global Drugs for Spinal Muscular Atrophy (SMA) Industry Ranking, 2023 VS 2024 VS 2025
- Global Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Manufacturing Sites & Headquarters
- Global Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Product Type & Application
- Global Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Established Date
- Global Drugs for Spinal Muscular Atrophy (SMA) Market CR5 and HHI
- Global Manufacturers Mergers & Acquisition
- Manufacturers Profiled
- Novartis
- Novartis Company Information
- Novartis Business Overview
- Novartis Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue and Gross Margin (2020-2025)
- Novartis Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
- Novartis Recent Developments
- Ionis Pharmaceuticals
- Ionis Pharmaceuticals Company Information
- Ionis Pharmaceuticals Business Overview
- Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue and Gross Margin (2020-2025)
- Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
- Ionis Pharmaceuticals Recent Developments
- Genentech
- Genentech Company Information
- Genentech Business Overview
- Genentech Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue and Gross Margin (2020-2025)
- Genentech Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
- Genentech Recent Developments
- Biogen
- Biogen Company Information
- Biogen Business Overview
- Biogen Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue and Gross Margin (2020-2025)
- Biogen Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
- Biogen Recent Developments
- Novartis
- Global Drugs for Spinal Muscular Atrophy (SMA) Market Scenario by Region
- Global Drugs for Spinal Muscular Atrophy (SMA) Market Size by Region: 2020 VS 2024 VS 2031
- Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region: 2020-2031
- Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region: 2020-2025
- Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region: 2026-2031
- Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region: 2020-2031
- Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region: 2020-2025
- Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region: 2026-2031
- North America Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Country
- North America Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2020 VS 2024 VS 2031
- North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2020-2031)
- North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2020-2031)
- United States
- Canada
- Mexico
- Europe Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Country
- Europe Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2020 VS 2024 VS 2031
- Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2020-2031)
- Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2020-2031)
- Germany
- France
- U.K.
- Italy
- Russia
- Spain
- Netherlands
- Switzerland
- Sweden
- Poland
- Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Country
- Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2020 VS 2024 VS 2031
- Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2020-2031)
- Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2020-2031)
- China
- Japan
- South Korea
- India
- Australia
- Taiwan
- Southeast Asia
- South America Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Country
- South America Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2020 VS 2024 VS 2031
- South America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2020-2031)
- South America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2020-2031)
- Brazil
- Argentina
- Chile
- Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Country
- Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2020 VS 2024 VS 2031
- Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2020-2031)
- Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2020-2031)
- Egypt
- South Africa
- Israel
- Türkiye
- GCC Countries
- Segment by Type
- Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2020-2031)
- Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2020-2031) & (K Units)
- Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2020-2031)
- Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2020-2031)
- Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2020-2031) & (US$ Million)
- Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2020-2031)
- Global Drugs for Spinal Muscular Atrophy (SMA) Price by Type (2020-2031)
- Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2020-2031)
- Segment by Application
- Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2020-2031)
- Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2020-2031) & (K Units)
- Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2020-2031)
- Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2020-2031)
- Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2020-2031) & (US$ Million)
- Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2020-2031)
- Global Drugs for Spinal Muscular Atrophy (SMA) Price by Application (2020-2031)
- Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2020-2031)
- Value Chain and Sales Channels Analysis of the Market
- Drugs for Spinal Muscular Atrophy (SMA) Value Chain Analysis
- Drugs for Spinal Muscular Atrophy (SMA) Key Raw Materials
- Raw Materials Key Suppliers
- Drugs for Spinal Muscular Atrophy (SMA) Production Mode & Process
- Drugs for Spinal Muscular Atrophy (SMA) Sales Channels Analysis
- Direct Comparison with Distribution Share
- Drugs for Spinal Muscular Atrophy (SMA) Distributors
- Drugs for Spinal Muscular Atrophy (SMA) Customers
- Drugs for Spinal Muscular Atrophy (SMA) Value Chain Analysis
- Global Drugs for Spinal Muscular Atrophy (SMA) Analyzing Market Dynamics
- Drugs for Spinal Muscular Atrophy (SMA) Industry Trends
- Drugs for Spinal Muscular Atrophy (SMA) Industry Drivers
- Drugs for Spinal Muscular Atrophy (SMA) Industry Opportunities and Challenges
- Drugs for Spinal Muscular Atrophy (SMA) Industry Restraints
- Report Conclusion
- Disclaimer
List of Tables
Table 1 | :Secondary Sources |
Table 2 | :Primary Sources |
Table 3 | :Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million) |
Table 4 | :Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million) |
Table 5 | :Global Drugs for Spinal Muscular Atrophy (SMA) Volume and Revenue Market Size and CAGR of Manufacturers (2020 Versus 2024) |
Table 6 | :Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units) of Manufacturers (2020-2025) |
Table 7 | :Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Manufacturers (2020-2025) |
Table 8 | :Global Drugs for Spinal Muscular Atrophy (SMA) Revenue of Manufacturers (2020-2025) |
Table 9 | :Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Manufacturers (2020-2025) |
Table 10 | :Global Market Drugs for Spinal Muscular Atrophy (SMA) Average Price (US$/Unit) of Manufacturers (2020-2025) |
Table 11 | :Global Drugs for Spinal Muscular Atrophy (SMA) Industry Ranking, 2023 VS 2024 VS 2025 |
Table 12 | :Global Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Manufacturing Sites & Headquarters |
Table 13 | :Global Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Product Type & Application |
Table 14 | :Global Drugs for Spinal Muscular Atrophy (SMA) Manufacturers Established Date |
Table 15 | :Global Manufacturers Market Concentration Ratio (CR5 and HHI) |
Table 16 | :Global Drugs for Spinal Muscular Atrophy (SMA) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024) |
Table 17 | :Manufacturers Mergers & Acquisitions, Expansion Plans) |
Table 18 | :Novartis Company Information |
Table 19 | :Novartis Business Overview |
Table 20 | :Novartis Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025) |
Table 21 | :Novartis Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio |
Table 22 | :Novartis Recent Developments |
Table 23 | :Ionis Pharmaceuticals Company Information |
Table 24 | :Ionis Pharmaceuticals Business Overview |
Table 25 | :Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025) |
Table 26 | :Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio |
Table 27 | :Ionis Pharmaceuticals Recent Developments |
Table 28 | :Genentech Company Information |
Table 29 | :Genentech Business Overview |
Table 30 | :Genentech Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025) |
Table 31 | :Genentech Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio |
Table 32 | :Genentech Recent Developments |
Table 33 | :Biogen Company Information |
Table 34 | :Biogen Business Overview |
Table 35 | :Biogen Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025) |
Table 36 | :Biogen Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio |
Table 37 | :Biogen Recent Developments |
Table 38 | :Global Drugs for Spinal Muscular Atrophy (SMA) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031 |
Table 39 | :Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (2020-2025) & (K Units) |
Table 40 | :Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Region (2020-2025) |
Table 41 | :Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (2026-2031) & (K Units) |
Table 42 | :Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Region (2026-2031) |
Table 43 | :Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (2020-2025) & (US$ Million) |
Table 44 | :Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Region (2020-2025) |
Table 45 | :Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (2026-2031) & (US$ Million) |
Table 46 | :Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Region (2026-2031) |
Table 47 | :North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million) |
Table 48 | :North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2020-2025) & (K Units) |
Table 49 | :North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2026-2031) & (K Units) |
Table 50 | :North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2020-2025) & (US$ Million) |
Table 51 | :North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2026-2031) & (US$ Million) |
Table 52 | :Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million) |
Table 53 | :Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2020-2025) & (K Units) |
Table 54 | :Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2026-2031) & (K Units) |
Table 55 | :Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2020-2025) & (US$ Million) |
Table 56 | :Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2026-2031) & (US$ Million) |
Table 57 | :Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million) |
Table 58 | :Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2020-2025) & (K Units) |
Table 59 | :Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2026-2031) & (K Units) |
Table 60 | :Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2020-2025) & (US$ Million) |
Table 61 | :Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2026-2031) & (US$ Million) |
Table 62 | :South America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million) |
Table 63 | :South America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2020-2025) & (K Units) |
Table 64 | :South America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2026-2031) & (K Units) |
Table 65 | :South America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2020-2025) & (US$ Million) |
Table 66 | :South America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2026-2031) & (US$ Million) |
Table 67 | :Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million) |
Table 68 | :Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2020-2025) & (K Units) |
Table 69 | :Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2026-2031) & (K Units) |
Table 70 | :Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2020-2025) & (US$ Million) |
Table 71 | :Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2026-2031) & (US$ Million) |
Table 72 | :Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2020-2025) & (K Units) |
Table 73 | :Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2026-2031) & (K Units) |
Table 74 | :Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2020-2025) |
Table 75 | :Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2026-2031) |
Table 76 | :Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2020-2025) & (US$ Million) |
Table 77 | :Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2026-2031) & (US$ Million) |
Table 78 | :Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2020-2025) |
Table 79 | :Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2026-2031) |
Table 80 | :Global Drugs for Spinal Muscular Atrophy (SMA) Price by Type (2020-2025) & (US$/Unit) |
Table 81 | :Global Drugs for Spinal Muscular Atrophy (SMA) Price by Type (2026-2031) & (US$/Unit) |
Table 82 | :Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2020-2025) & (K Units) |
Table 83 | :Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2026-2031) & (K Units) |
Table 84 | :Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2020-2025) |
Table 85 | :Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2026-2031) |
Table 86 | :Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2020-2025) & (US$ Million) |
Table 87 | :Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2026-2031) & (US$ Million) |
Table 88 | :Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2020-2025) |
Table 89 | :Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2026-2031) |
Table 90 | :Global Drugs for Spinal Muscular Atrophy (SMA) Price by Application (2020-2025) & (US$/Unit) |
Table 91 | :Global Drugs for Spinal Muscular Atrophy (SMA) Price by Application (2026-2031) & (US$/Unit) |
Table 92 | :Key Raw Materials |
Table 93 | :Raw Materials Key Suppliers |
Table 94 | :Drugs for Spinal Muscular Atrophy (SMA) Distributors List |
Table 95 | :Drugs for Spinal Muscular Atrophy (SMA) Customers List |
Table 96 | :Drugs for Spinal Muscular Atrophy (SMA) Industry Trends |
Table 97 | :Drugs for Spinal Muscular Atrophy (SMA) Industry Drivers |
Table 98 | :Drugs for Spinal Muscular Atrophy (SMA) Industry Restraints |
Table 99 | :Authors List of This Report |
List of Figures
Figure 1 | :Research Methodology |
Figure 2 | :Research Process |
Figure 3 | :Key Executives Interviewed |
Figure 4 | :Drugs for Spinal Muscular Atrophy (SMA) Product Image |
Figure 5 | :Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (US$ Million), 2020 VS 2024 VS 2031 |
Figure 6 | :Global Drugs for Spinal Muscular Atrophy (SMA) Market Size (2020-2031) & (US$ Million) |
Figure 7 | :Global Drugs for Spinal Muscular Atrophy (SMA) Sales (2020-2031) & (K Units) |
Figure 8 | :Global Drugs for Spinal Muscular Atrophy (SMA) Average Price (US$/Unit) & (2020-2031) |
Figure 9 | :Oral Drugs Product Image |
Figure 10 | :Injections Product Image |
Figure 11 | :Hospital Product Image |
Figure 12 | :Clinic Product Image |
Figure 13 | :Other Product Image |
Figure 14 | :Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Manufacturers in 2024 |
Figure 15 | :Global Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Manufacturing Sites & Headquarters |
Figure 16 | :Global Top 5 and 10 Drugs for Spinal Muscular Atrophy (SMA) Players Market Share by Revenue in 2024 |
Figure 17 | :Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024 |
Figure 18 | :Global Drugs for Spinal Muscular Atrophy (SMA) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031 |
Figure 19 | :Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region in 2024 |
Figure 20 | :Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region in 2024 |
Figure 21 | :North America Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country in 2024 |
Figure 22 | :North America Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2020-2031) |
Figure 23 | :North America Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Country (2020-2031) |
Figure 24 | :United States Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 25 | :Canada Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 26 | :Mexico Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 27 | :Europe Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country in 2024 |
Figure 28 | :Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2020-2031) |
Figure 29 | :Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Country (2020-2031) |
Figure 30 | :Germany Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 31 | :France Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 32 | :U.K. Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 33 | :Italy Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 34 | :Russia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 35 | :Spain Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 36 | :Netherlands Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 37 | :Switzerland Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 38 | :Sweden Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 39 | :Poland Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 40 | :Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country in 2024 |
Figure 41 | :Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2020-2031) |
Figure 42 | :Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Country (2020-2031) |
Figure 43 | :China Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 44 | :Japan Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 45 | :South Korea Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 46 | :India Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 47 | :Australia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 48 | :Taiwan Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 49 | :Southeast Asia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 50 | :Southeast Asia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 51 | :South America Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country in 2024 |
Figure 52 | :South America Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2020-2031) |
Figure 53 | :South America Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Country (2020-2031) |
Figure 54 | :Brazil Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 55 | :Argentina Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 56 | :Chile Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 57 | :Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country in 2024 |
Figure 58 | :Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2020-2031) |
Figure 59 | :Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Country (2020-2031) |
Figure 60 | :Egypt Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 61 | :South Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 62 | :Israel Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 63 | :Türkiye Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 64 | :GCC Countries Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2020-2031) & (US$ Million) |
Figure 65 | :Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2020-2031) |
Figure 66 | :Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2020-2031) |
Figure 67 | :Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Type (2020-2031) |
Figure 68 | :Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2020-2031) |
Figure 69 | :Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2020-2031) |
Figure 70 | :Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Application (2020-2031) |
Figure 71 | :Drugs for Spinal Muscular Atrophy (SMA) Value Chain |
Figure 72 | :Drugs for Spinal Muscular Atrophy (SMA) Production Mode & Process |
Figure 73 | :Direct Comparison with Distribution Share |
Figure 74 | :Distributors Profiles |
Figure 75 | :Drugs for Spinal Muscular Atrophy (SMA) Industry Opportunities and Challenges |
Request a Sample
Sample excerpt is intended to facilitate an informed purchase decision. Its purpose is not to offer free information or act as a substitute for the comprehensive product. In order to tailor the sample to your specific requirements, we will reach out to you to gather more details about your criteria.

Pharma & Healthcare
Drugs for Spinal Muscular Atrophy (SMA) Industry Research Report 2025
Pages: 111
Complete Your Request
Customer reviews
- 0 out of 5
- 0 Reviews
5
4
3
2
1
No Rating Review Exist.
Write Review
Suggested Report
View MoreNo data found.